Platinum-Based Brush-Arm Star Polymers for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Platinum-based therapeutics, such as cisplatin, face significant dose-limiting toxicities like nephrotoxicity and neurotoxicity, limiting their effectiveness in cancer treatment due to adverse reactions, and existing delivery methods fail to provide controlled release specifically to cancer cells while minimizing harm to normal tissues.
Innovation Solution
The development of platinum-based brush-arm star polymers (Pt-BASPs) using 'brush-first' ring-opening metathesis polymerization, which forms unimolecular micelle-like nanostructures with a core and corona, allowing for the controlled release of platinum-based agents like cisplatin and potential combination therapies, utilizing platinum complexes as crosslinkers and macromonomers to create polymers that can be tailored for targeted drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based therapeutics like cisplatin are used at higher doses to achieve maximum antineoplastic effects, then the therapeutic efficacy is improved, but the nephrotoxicity and neurotoxicity increase significantly
Solution Approach 1:
The patent segments the platinum-based therapeutic delivery system into distinct functional components: a hydrophobic core containing the platinum agent and a hydrophilic corona for biocompatibility and targeting. This segmentation allows the therapeutic to be delivered in a controlled manner that reduces systemic toxicity while maintaining efficacy at the tumor site.
Solution Approach 2:
The polymer brush-arm star structure acts as an intermediary carrier between the platinum-based therapeutic and the biological system. This intermediary structure protects the therapeutic from premature degradation, controls its release kinetics, and reduces direct toxic interactions with healthy tissues while maintaining therapeutic activity.
2Quantity of substance
If conventional delivery methods are used to administer platinum-based agents, then the drug can be delivered systemically, but the drug cannot be released in a controlled manner and accumulates in non-target tissues
Solution Approach 1:
The patent applies local quality by creating a core-corona structure where the hydrophobic core provides localized high concentration of the platinum therapeutic, while the hydrophilic corona provides localized biocompatibility and targeting functionality. This spatial differentiation of properties enables controlled release at the target site while minimizing accumulation in non-target tissues.
Solution Approach 2:
The patent utilizes parameter changes in the polymer structure (molecular weight, brush density, corona composition) to control the release kinetics and targeting properties of the platinum-based therapeutic, enabling tailored delivery profiles for different therapeutic scenarios.
3Device complexity
If single-agent delivery is used, then the delivery system is simpler, but the ability to provide combination therapies is limited
Solution Approach 1:
The patent designs the polymer brush-arm star structure with universal functionality that can accommodate multiple different therapeutic agents (platinum-based agents, taxanes, antimetabolites, etc.) within its core, enabling a single delivery platform to perform multiple therapeutic functions and combination therapies.
Solution Approach 2:
The patent employs composite material strategies by combining different therapeutic agents within the same polymer carrier structure, creating a multifunctional composite system that delivers multiple agents simultaneously or in a controlled sequence to enhance therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Pt-BASPs enable the controlled and targeted delivery of platinum-based agents, reducing toxic side effects by maintaining therapeutic levels over time and allowing for the simultaneous delivery of multiple therapeutic agents, enhancing the efficacy of cancer treatment while minimizing harm to healthy tissues.
Implementation Method 1
platinum-based brush-arm star polymers (Pt-BASPs) using 'brush-first' ring-opening metathesis polymerization (ROMP)
Data Source
AI summary
Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as cisplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.